Ming Poi
YOU?
Author Swipe
View article: Multidimensional Analysis of B7 Homolog 3 RNA Expression in Small Cell Lung Cancer Molecular Subtypes
Multidimensional Analysis of B7 Homolog 3 RNA Expression in Small Cell Lung Cancer Molecular Subtypes Open
Purpose: B7 homolog 3 (B7-H3) is a promising target for antibody–drug conjugates, with ifinatamab deruxtecan demonstrating an objective response rate of 54.8% in previously treated extensive-stage small cell lung cancer (SCLC). This analys…
View article: Trametinib Synergized With Abemaciclib to Inhibit Tumor Growth in Human Head and Neck Squamous Cell Carcinoma Cells
Trametinib Synergized With Abemaciclib to Inhibit Tumor Growth in Human Head and Neck Squamous Cell Carcinoma Cells Open
The combination of abemaciclib and trametinib potently repressed the growth of HNSCC cells and xenografts in a synergistic manner, thus being a potential therapeutic approach for HNSCC.
View article: Genetic Alteration of<i>p18<sup>INK4C</sup></i>and its Expression in Peripheral Blood Mononuclear Cells Were Not Associated With Progression-free Survival of Multiple Myeloma Patients After Autologous Stem Cell Transplant
Genetic Alteration of<i>p18<sup>INK4C</sup></i>and its Expression in Peripheral Blood Mononuclear Cells Were Not Associated With Progression-free Survival of Multiple Myeloma Patients After Autologous Stem Cell Transplant Open
Neither p18 deletion nor p18 mRNA expression in PBMCs can be used as a prognostic biomarker in MM patients.
View article: CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation
CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation Open
Introduction: Polymorphisms in genes responsible for the metabolism and transport of tacrolimus have been demonstrated to influence clinical outcomes for patients following allogeneic hematologic stem cell transplant (allo-HSCT). However, …
View article: Supplementary Figure Legends from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines
Supplementary Figure Legends from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines Open
Supplementary Figure Legends
View article: Data from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines
Data from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines Open
Optimally effective antitumor therapies would not only activate immune effector cells but also engage them at the tumor. Folate conjugated to immunoglobulin (F-IgG) could direct innate immune cells with Fc receptors to folate receptor–expr…
View article: Data from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines
Data from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines Open
Optimally effective antitumor therapies would not only activate immune effector cells but also engage them at the tumor. Folate conjugated to immunoglobulin (F-IgG) could direct innate immune cells with Fc receptors to folate receptor–expr…
View article: Supplemental Figures 1-3 from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines
Supplemental Figures 1-3 from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines Open
Supplemental Figure 1.F‑IgG and IL-12 mediated NK cell lysis is dependent on the folate receptor availability and does not correlate with FcR genotype. Supplemental Figure 2. MDSC inhibit NK cell lytic activity and IFN-y production. Supp…
View article: Supplemental Figures 1-3 from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines
Supplemental Figures 1-3 from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines Open
Supplemental Figure 1.F‑IgG and IL-12 mediated NK cell lysis is dependent on the folate receptor availability and does not correlate with FcR genotype. Supplemental Figure 2. MDSC inhibit NK cell lytic activity and IFN-y production. Supp…
View article: Supplementary Figure Legends from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines
Supplementary Figure Legends from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines Open
Supplementary Figure Legends
View article: Data from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Data from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
Purpose: Flavopiridol, the first clinically evaluated cyclin-dependent kinase inhibitor, shows activity in patients with refractory chronic lymphocytic leukemia, but prevalent and unpredictable tumor lysis syndrome (TLS) presents a major b…
View article: Supplementary Figure Legends from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Figure Legends from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 51 KB
View article: Supplementary Tables 1-2 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Tables 1-2 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 79 KB, Supplementary Table 1. Patient Characteristics Supplementary Table 2. Summary of drop-outs in Cycle 1
View article: Supplementary Figure Legends from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Figure Legends from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 51 KB
View article: Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 255 KB, Figure 1. Flavopiridol conditional weighted residuals vs. time with a smoothed loess line. Figure 2. Flavopiridol conditional weighted residuals vs. population predicted values with a smoothed loess line. Figure 3. Visua…
View article: Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 255 KB, Figure 1. Flavopiridol conditional weighted residuals vs. time with a smoothed loess line. Figure 2. Flavopiridol conditional weighted residuals vs. population predicted values with a smoothed loess line. Figure 3. Visua…
View article: Supplementary Tables 1-2 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Supplementary Tables 1-2 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
PDF file - 79 KB, Supplementary Table 1. Patient Characteristics Supplementary Table 2. Summary of drop-outs in Cycle 1
View article: Data from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Data from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Open
Purpose: Flavopiridol, the first clinically evaluated cyclin-dependent kinase inhibitor, shows activity in patients with refractory chronic lymphocytic leukemia, but prevalent and unpredictable tumor lysis syndrome (TLS) presents a major b…
View article: <i>PARP1</i> and <i>POLD2</i> as prognostic biomarkers for multiple myeloma in autologous stem cell transplant
<i>PARP1</i> and <i>POLD2</i> as prognostic biomarkers for multiple myeloma in autologous stem cell transplant Open
Multiple Myeloma (MM) is an incurable plasma cell malignancy often treated by autologous stem cell transplant (ASCT). Clinical response to ASCT has been associated with DNA repair efficiency. Here we interrogated the role of the base excis…
View article: Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant
Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant Open
CYP3A4*1B/*1B and CYP3A5*3/*3 variations might influence melphalan therapy in MM patients through yet-to-be-identified mechanisms.
View article: Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i> -Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial
Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i> -Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial Open
Background: Oncogenic BRAF mutations are commonly found in advanced differentiated thyroid cancer (DTC), and reports have shown efficacy of BRAF inhibitors in these tumors. We investigated the difference in response between dabrafenib mono…
View article: A Single Nucleotide Polymorphism (SNP) in the<i>SLC22A3</i>Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy
A Single Nucleotide Polymorphism (SNP) in the<i>SLC22A3</i>Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy Open
OCT3 might be involved in melphalan transport in MM patients.
View article: Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK Open
Neurofibromatosis Type 2 (NF2) is an autosomal dominant genetic syndrome caused by mutations in the NF2 tumor suppressor gene resulting in multiple schwannomas and meningiomas. There are no FDA approved therapies for these tumors and their…
View article: Factors Predicting Participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky
Factors Predicting Participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky Open
Purpose Large‐scale genomic sequencing studies are driving oncology drug development. However, rural populations, like those residing in Appalachian Kentucky, are underrepresented in these efforts. In this study, we determined the frequenc…
View article: Cisplatin Induced the Expression of<i>SEI1</i>(<i>TRIP-Br1</i>) Oncogene in Human Oral Squamous Cancer Cell Lines
Cisplatin Induced the Expression of<i>SEI1</i>(<i>TRIP-Br1</i>) Oncogene in Human Oral Squamous Cancer Cell Lines Open
Cisplatin-induced up-regulation of SEI1 expression in OSCC is specific, and such induction could underlie the development of resistance to cisplatin in OSCC.
View article: PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines
PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines Open
PTC209 (BMI1-targeting agents, in general) represents a novel chemotherapeutic agent with potential in cervical cancer therapy.